50 results
ARS
2024 FY
ABSI
Absci Corp
23 Apr 24
Annual report to shareholders
4:10pm
to design highly specific, safe therapeutics for a wide variety of disease targets less addressable by small molecules. Absci was founded on a technology … their corresponding antigens, offering new therapeutic targets, as well as the cognate binding partners, for further potential validation and optimization. AI
424B5
ABSI
Absci Corp
28 Feb 24
Prospectus supplement for primary offering
8:34am
pipeline: We aim to create therapeutic assets comprising our own internal program pipeline. With the ability to find targets and develop potential best … novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. We believe
8-K
ABSI
Absci Corp
27 Feb 24
Results of Operations and Financial Condition
4:45pm
targets and develop potential best-in-class assets, we intend to develop promising assets to value inflection points, anywhere from preclinical
424B5
gey9yi7zxpcg0 96qxl
27 Feb 24
Prospectus supplement for primary offering
4:40pm
8-K
EX-99.1
a9p 9mh3l
8 Jan 24
Absci Corporation 2024 All Rights Reserved 42ND JP Morgan Healthcare Conference
7:08am
8-K
EX-99.1
2gs5qkiyxkduwbeo 6e
20 Dec 23
Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline
8:30am
8-K
EX-99.1
tsz9btqw4f 482z
4 Dec 23
Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate
7:31am
8-K
EX-99.2
rl1hez
14 Nov 23
Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results
4:40pm
8-K
EX-99.1
x6lq4r of57n
14 Nov 23
Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results
4:40pm
8-K
EX-99.1
ot7br64
14 Aug 23
Absci Reports Business Updates and Second Quarter 2023 Financial and Operating Results
8:13am
424B5
wa3amgohh mgl6agg
16 Jun 23
Prospectus supplement for primary offering
4:45pm
8-K
EX-99.1
i5x8w
15 May 23
Absci Reports Business Updates and First Quarter 2023 Financial and Operating Results
4:08pm
ARS
2of8h78w2 y9korndru
28 Apr 23
Annual report to shareholders
12:00am
PRE 14A
q8tc3ymq79liysk0ebu
11 Apr 23
Preliminary proxy
5:49pm